---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-110103"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-10-20T23:59:59+00:00"
generated_at: "2026-06-23T02:20:54.841831+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA signs collaboration with Roche for KRAS-mutated cancer therapy; $25M upfront, up to $930M milestones

## Summary
- HOOKIPA receives $25 million upfront; eligible for up to ~$930 million in total milestone payments plus tiered royalties.
- Roche licenses HB-700, an arenaviral immunotherapy for KRAS-mutated cancers; HOOKIPA conducts research through Phase 1b.
- Roche obtains an exclusive option to license a second undisclosed arenaviral immunotherapy for an additional $15 million payment.
- Tiered royalties of high single-digit to mid-teens percent on worldwide net sales for both programs upon commercialization.
- First oncology licensing collaboration for HOOKIPA; partnership validates its arenavirus platform.

## SEC filing metadata
- accession: 0001104659-22-110103
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-10-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465922110103/0001104659-22-110103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465922110103/tm2228531d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-110103
- JSON: https://secwatch.observer/filing/0001104659-22-110103.json
- Plain text: https://secwatch.observer/filing/0001104659-22-110103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.